These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28820270)

  • 1. Second line treatment options for pancreatic cancer.
    Passero FC; Saif MW
    Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Screening to Treatment of Pancreatic Cancer: A Comprehensive Review.
    Saif MW
    JOP; 2021; 22(3):70-79. PubMed ID: 34483790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
    Passero FC; Grapsa D; Syrigos KN; Saif MW
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):697-703. PubMed ID: 27219482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
    Sohal DPS; Kennedy EB; Khorana A; Copur MS; Crane CH; Garrido-Laguna I; Krishnamurthi S; Moravek C; O'Reilly EM; Philip PA; Ramanathan RK; Ruggiero JT; Shah MA; Urba S; Uronis HE; Lau MW; Laheru D
    J Clin Oncol; 2018 Aug; 36(24):2545-2556. PubMed ID: 29791286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Sohal DP; Mangu PB; Khorana AA; Shah MA; Philip PA; O'Reilly EM; Uronis HE; Ramanathan RK; Crane CH; Engebretson A; Ruggiero JT; Copur MS; Lau M; Urba S; Laheru D
    J Clin Oncol; 2016 Aug; 34(23):2784-96. PubMed ID: 27247222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
    Garcia G; Odaimi M
    J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
    Aprile G; Negri FV; Giuliani F; De Carlo E; Melisi D; Simionato F; Silvestris N; Brunetti O; Leone F; Marino D; Santini D; Dell'Aquila E; Zeppola T; Puzzoni M; Scartozzi M
    Crit Rev Oncol Hematol; 2017 Jul; 115():1-12. PubMed ID: 28602164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Currently available first-line drug therapies for treating pancreatic cancer.
    Olson JL; Bold RJ
    Expert Opin Pharmacother; 2018 Dec; 19(17):1927-1940. PubMed ID: 30325679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
    Cinar P; Ko AH
    Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.
    Collins DC; Morris PG
    Expert Opin Pharmacother; 2015 Apr; 16(6):851-61. PubMed ID: 25773342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
    Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
    Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    Ramfidis VS; Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Jul; 13(4):358-60. PubMed ID: 22797389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
    Ueno M
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.